Social value of statins merits actions to broaden treatment, improve adherence, study finds
Article
New evidence suggests that statins generate large survival and health benefits at the population level and greater use of and adherence to statins should be encouraged, according to a study published in the October issue of Health Affairs.
Social value of statins merits actions to broaden treatment, improve adherence, study finds
New evidence suggests that statins generate large survival and health benefits at the population level and greater use of and adherence to statins should be encouraged, according to a study published in the October issue of Health Affairs.
Mifepristone Reduces HbA1c in Patients With T2D, Hypercortisolism | ADA 2025
Results from the CATALYST trial showed patients who received mifepristone had a mean HbA1c reduction of 1.47%,
How the Complexities, Trends in Drug Benefit Design Are Evolving in Real Time
With the emergence of increased GLP-1 use and alternative PBM models, Morgan Lee, PhD, MPH, CPH, and Scott Halperin, PharmD, joined Drug Topics to discuss current trends in drug benefit design.
Q&A: Creating a Pharmacy Where Technicians Can Thrive
Pharmacy technicians must be recognized and empowered as essential, long-term professionals to improve workplace well-being, patient care, and pharmacy success.
The Independent Pharmacist Championing Innovative, Patient-Centric Care
Amid the continuously evolving role of pharmacists in today’s health care landscape, independent owners like Amina Abubakar, PharmD, AAHIVP, are advancing the profession through innovation.
Whitepaper: 10 Critical RFP Questions for Choosing a Centralized Fulfillment Partner
June 26th 2025GLP-1 Use Increased Significantly Among Pediatric Patients With T2D in Past 5 Years | ADA 2025
From 2019 to 2024, GLP-1 prescriptions among pediatric patients with type 2 diabetes increased from 12.3% to 60.9%.
Mifepristone Reduces HbA1c in Patients With T2D, Hypercortisolism | ADA 2025
Results from the CATALYST trial showed patients who received mifepristone had a mean HbA1c reduction of 1.47%,
How the Complexities, Trends in Drug Benefit Design Are Evolving in Real Time
With the emergence of increased GLP-1 use and alternative PBM models, Morgan Lee, PhD, MPH, CPH, and Scott Halperin, PharmD, joined Drug Topics to discuss current trends in drug benefit design.
Q&A: Creating a Pharmacy Where Technicians Can Thrive
Pharmacy technicians must be recognized and empowered as essential, long-term professionals to improve workplace well-being, patient care, and pharmacy success.
The Independent Pharmacist Championing Innovative, Patient-Centric Care
Amid the continuously evolving role of pharmacists in today’s health care landscape, independent owners like Amina Abubakar, PharmD, AAHIVP, are advancing the profession through innovation.
Whitepaper: 10 Critical RFP Questions for Choosing a Centralized Fulfillment Partner
June 26th 2025GLP-1 Use Increased Significantly Among Pediatric Patients With T2D in Past 5 Years | ADA 2025
From 2019 to 2024, GLP-1 prescriptions among pediatric patients with type 2 diabetes increased from 12.3% to 60.9%.